Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market to Reach $11.53 Billion by 2029 | Key Drivers and Future Outlook
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market In 2029?
The market size of contract development and manufacturing organizations (CDMOs) for advanced therapy medicinal products has experienced noteworthy growth in recent years. The market, which is projected to rise from $5.31 billion in 2024 to $6.22 billion in 2025, boasts a compound annual growth rate (CAGR) of 17.0%. The historical growth can be attributed to factors such as a hike in ATMP clinical trials, increased awareness and conviction among researchers about the benefits of advanced therapy, the myriad of ATMP CDMOs in existence, heightened efforts geared towards the development of new treatments for various diseases, and the backing of government initiatives.
What Growth Rate Is Forecasted for the Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market by 2029?
The market for contract development and manufacturing organizations (CDMOs) specializing in advanced therapy medicinal products is slated for a significant upswing in the coming years, expected to expand to a valuation of $11.53 billion by 2029. This represents a compound annual growth rate (CAGR) of 16.7%. Factors contributing to this impressive growth rate include the increased financial commitment of CDMOs, a surge in new entities in the cell and gene therapy (CGT) field, a rise in grants and funding for cell and gene therapy development, an escalation in pharmaceutical R&D expenditure, and a growing count of trials for ATMPs. Key trends within this growth period encompass enhancements in AAV biomanufacturing facilities, the broadening of cell and gene therapy manufacturing, advancements in cellular and gene therapy technology, an amplified demand for advanced platforms and technologies, and the integration of cutting-edge technologies like CRISPR and next-generation sequencing for improved precision.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15719&type=smp
Which Key Companies Are Shaping the Future of the Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market?
Major companies operating in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) market are Thermo Fisher Scientific Inc., Merck KGaA, Resonac Corporation, Lonza Group AG, Catalent Inc., Charles River Laboratories International Inc., Recipharm AB, KBI Biopharma, Takara Bio Inc., Rentschler Biopharma SE, Ajinomoto Co. Inc., ElevateBio LLC, Fujifilm Diosynth Biotechnologies, Axplora Group GmbH, WuXi Advanced Therapies Inc., Celonic Group, Batavia Biosciences B.V., BioCentriq, Cytovance Biologics, Andelyn Biosciences, Genezen, AGC Biologics, ABL Manufacturing, Minaris Regenerative Medicine, Porton Advanced Solutions
Which Factors Are Driving Demand in the Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Industry?
The growth of the advanced therapy medicinal products CDMO market is anticipated to be driven by the rising number of clinical trials. Clinical trials, which are research studies in humans to assess the safety and effectiveness of medical interventions such as drugs, treatments, devices, or preventative measures, are increasing to satisfy the growing requirement for innovative therapies and to tackle the rising global disease burden. The demand for CDMO manufacturing services spikes with the application of advanced therapy medicinal products, utilizing specialized proficiency and infrastructure. The data derived from clinical trials contributes to streamlining manufacturing, ensuring scalability, and maintaining quality to meet larger clinical and commercial needs. For example, figures from the Association of the British Pharmaceutical Industry, a UK-based trade association, revealed that the overall number of industry clinical trials initiated in the UK annually marginally rose by 4.3%, from 394 in 2021 to 411 in 2022. Consequently, the advanced therapy medicinal products CDMO market is propelled by the increasing number of clinical trials.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=15719&type=smp
How Is the Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market Segmented by Several Divisions?
The advanced therapy medicinal products contract development and manufacturing organization (CDMO) market covered in this report is segmented –
1) By Product: Gene Therapy, Cell Therapy, Tissue Engineered
2) By Phase: Phase I, Phase II, Phase III, Phase IV
3) By Indication: Oncology, Cardiology, Central Nervous System And Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology And Inflammation, Ophthalmology, Hematology
Subsegments:
1) By Gene Therapy: Viral Vectors, Non-Viral Vectors, Dna Or Rna-Based Products
2) By Cell Therapy: Autologous Cell Therapy, Allogeneic Cell Therapy, Stem Cell Therapy
3) By Tissue Engineered: Skin Substitutes, Cartilage And Bone Tissue, Vascular Grafts And Organs
What are the Emerging Market Trends Driving the Growth of the Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Industry?
Leading companies involved in the advanced therapy medicinal products CDMO market are innovating cell therapy production services to address pressing challenges in cell therapy creation and accelerate their partners’ development operations. Contract development and manufacturing services specializing in cell therapy cover a range of provisions from early preclinical development to late-stage clinical trials and market entry. For instance, Pluristem Therapeutics Inc., a biotech company based in Israel known for cell solutions, introduced PluriCDMO in January 2024. The new business division focuses on cell therapy manufacturing, employing a patented bioreactor system for 3D cell multiplication. This system helps in producing various cell types like stem cells, induced pluripotent stem cells, exosomes, and immune therapies. The goal of PluriCDMO is to deliver crucial, high-quality medicines to patients, ensuring batch-to-batch consistency and scalability within a cost-effective and good manufacturing practice environment.
Access The Full Report Here:
Which Regions Are Driving Growth in the Advanced Therapy Medicinal Products Contract Development And Manufacturing Organization (CDMO) Market?
North America was the largest region in the advanced therapy medicinal product contract development and manufacturing organization (CDMO) market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced therapy medicinal products contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15719
This Report Delivers Insight On:
1. How big is the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market, and how is it changing globally?
2. Who are the major companies in the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market, and how are they performing?
3. What are the key opportunities and risks in the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market right now?
4. Which products or customer segments are growing the most in the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market?
5. What factors are helping or slowing down the growth of the advanced therapy medicinal products contract development and manufacturing organization (cdmo) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
